WFRF:(Nasic Salmir)
Sökning: WFRF:(Nasic Salmir) > Clinical evaluation...
- 17 av 52
- Föregående post
- Nästa post
- Till träfflistan
Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancer
-
- Janeva, Slavica (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin,Institute of Biomedicine
- Krabbe, E. (författare)
-
- Parris, Toshima Z, 1978 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology
- visa fler...
- Sundquist, M. (författare)
- visa färre...
- (creator_code:org_t)
- 2023
- 2023
- Engelska.
- Ingår i: Breast Cancer Research. - 1465-5411. ; 25:1
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- BackgroundWhen ipsilateral multifocal primary breast cancer (IMBC) is detected, standard routine is to evaluate the largest tumor with immunohistochemistry (IHC). As all foci are not routinely characterized, many patients may not receive optimal adjuvant treatment. Here, we assess the clinical relevance of examining at least two foci present in patients with IMBC.MethodsPatients diagnosed and treated for IMBC at Sahlgrenska University Hospital (Gothenburg, Sweden) between 2012 and 2017 were screened. In total, 180 patients with >= 2 invasive foci (183 specimens) were assessed with IHC and included in this study. Expression of the estrogen (ER) and progesterone (PR) receptors, Ki67, HER2, and tumor grade were used to determine the molecular surrogate subtypes and discordance among the foci was recorded. An additional multidisciplinary team board was then held to re-assess whether treatment recommendations changed due to discordances in molecular surrogate subtype between the different foci.ResultsDiscordance in ER, PR, HER2, and Ki67 was found in 2.7%, 19.1%, 7.7%, and 16.9% of invasive foci, respectively. Discordance in the molecular surrogate subtypes was found in 48 of 180 (26.7%) patients, which resulted in therapy changes for 11 patients (6.1%). These patients received additional endocrine therapy (n = 2), chemotherapy (n = 3), and combined chemotherapy and trastuzumab (n = 6).ConclusionTaken together, when assessing at least two tumor foci with IHC, regardless of shared morphology or tumor grade between the different foci, 6.1% of patients with IMBC were recommended additional adjuvant treatment. A pathologic assessment using IHC of all foci is therefore recommended to assist in individualized treatment decision making.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Multifocal breast cancer
- Multicentric breast cancer
- Biomarkers
- Breast
- cancer subtypes
- Adjuvant treatment
- Synchronous
- Discordant
- multicentric mammary-carcinoma
- 20-year follow-up
- mastectomy
- tumors
- size
- foci
- Oncology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
- 17 av 52
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Janeva, Slavica
- Krabbe, E.
- Parris, Toshima ...
- Nasic, Salmir
- Sundquist, M.
- Karlsson, Per, 1 ...
- visa fler...
- Audisio, Riccard ...
- Olofsson Bagge, ...
- Kovács, Anikó, 1 ...
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- Breast Cancer Re ...
- Av lärosätet
- Göteborgs universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
